Infectious complications of cancer chemotherapy in HIV patients

Raffaella Rosso, Antonio Di Biagio, Claudio Viscoli

Research output: Contribution to journalArticle

Abstract

The outcome for HIV-infected patients with cancer has dramatically improved in the highly active antiretroviral therapy (HAART) era, probably due to improvements in immune status and bone marrow function that allow the possibility of increased drug-dose intensity with a higher complete remission rate. Although data regarding the optimal management of these cancers are lacking, current studies suggest that patients with HIV-associated malignancies could be treated using approaches similar to those for their counterparts in the general population (ie, with chemotherapy, radiation, and appropriate use of supportive measures). In the HAART era, the AIDS-related mortality rate has decreased by approximately 70%, and so the cause of the growing number of reports of cancers in HIV patients is unclear. Clearly, non-AIDS-defining malignancies account for more morbidity and mortality than AIDS-defining malignancies. Prevention strategies are needed to adequately deal with HIV-associated cancers in an aging and growing HIV-positive population.

Original languageEnglish
Pages (from-to)149-156
Number of pages8
JournalCurrent Infectious Disease Reports
Volume10
Issue number2
DOIs
Publication statusPublished - Mar 2008

Fingerprint

HIV
Drug Therapy
Neoplasms
Highly Active Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Mortality
Population
Bone Marrow
Radiation
Morbidity
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Infectious complications of cancer chemotherapy in HIV patients. / Rosso, Raffaella; Di Biagio, Antonio; Viscoli, Claudio.

In: Current Infectious Disease Reports, Vol. 10, No. 2, 03.2008, p. 149-156.

Research output: Contribution to journalArticle

Rosso, Raffaella ; Di Biagio, Antonio ; Viscoli, Claudio. / Infectious complications of cancer chemotherapy in HIV patients. In: Current Infectious Disease Reports. 2008 ; Vol. 10, No. 2. pp. 149-156.
@article{ea9f97cf3f6d4641a8fd9c9be8c42dad,
title = "Infectious complications of cancer chemotherapy in HIV patients",
abstract = "The outcome for HIV-infected patients with cancer has dramatically improved in the highly active antiretroviral therapy (HAART) era, probably due to improvements in immune status and bone marrow function that allow the possibility of increased drug-dose intensity with a higher complete remission rate. Although data regarding the optimal management of these cancers are lacking, current studies suggest that patients with HIV-associated malignancies could be treated using approaches similar to those for their counterparts in the general population (ie, with chemotherapy, radiation, and appropriate use of supportive measures). In the HAART era, the AIDS-related mortality rate has decreased by approximately 70{\%}, and so the cause of the growing number of reports of cancers in HIV patients is unclear. Clearly, non-AIDS-defining malignancies account for more morbidity and mortality than AIDS-defining malignancies. Prevention strategies are needed to adequately deal with HIV-associated cancers in an aging and growing HIV-positive population.",
author = "Raffaella Rosso and {Di Biagio}, Antonio and Claudio Viscoli",
year = "2008",
month = "3",
doi = "10.1007/s11908-008-0026-7",
language = "English",
volume = "10",
pages = "149--156",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Infectious complications of cancer chemotherapy in HIV patients

AU - Rosso, Raffaella

AU - Di Biagio, Antonio

AU - Viscoli, Claudio

PY - 2008/3

Y1 - 2008/3

N2 - The outcome for HIV-infected patients with cancer has dramatically improved in the highly active antiretroviral therapy (HAART) era, probably due to improvements in immune status and bone marrow function that allow the possibility of increased drug-dose intensity with a higher complete remission rate. Although data regarding the optimal management of these cancers are lacking, current studies suggest that patients with HIV-associated malignancies could be treated using approaches similar to those for their counterparts in the general population (ie, with chemotherapy, radiation, and appropriate use of supportive measures). In the HAART era, the AIDS-related mortality rate has decreased by approximately 70%, and so the cause of the growing number of reports of cancers in HIV patients is unclear. Clearly, non-AIDS-defining malignancies account for more morbidity and mortality than AIDS-defining malignancies. Prevention strategies are needed to adequately deal with HIV-associated cancers in an aging and growing HIV-positive population.

AB - The outcome for HIV-infected patients with cancer has dramatically improved in the highly active antiretroviral therapy (HAART) era, probably due to improvements in immune status and bone marrow function that allow the possibility of increased drug-dose intensity with a higher complete remission rate. Although data regarding the optimal management of these cancers are lacking, current studies suggest that patients with HIV-associated malignancies could be treated using approaches similar to those for their counterparts in the general population (ie, with chemotherapy, radiation, and appropriate use of supportive measures). In the HAART era, the AIDS-related mortality rate has decreased by approximately 70%, and so the cause of the growing number of reports of cancers in HIV patients is unclear. Clearly, non-AIDS-defining malignancies account for more morbidity and mortality than AIDS-defining malignancies. Prevention strategies are needed to adequately deal with HIV-associated cancers in an aging and growing HIV-positive population.

UR - http://www.scopus.com/inward/record.url?scp=56349127814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349127814&partnerID=8YFLogxK

U2 - 10.1007/s11908-008-0026-7

DO - 10.1007/s11908-008-0026-7

M3 - Article

C2 - 18462590

AN - SCOPUS:56349127814

VL - 10

SP - 149

EP - 156

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 2

ER -